Compare RDIB & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDIB | MDWD |
|---|---|---|
| Founded | 1937 | 2000 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.7M | 224.6M |
| IPO Year | N/A | 2013 |
| Metric | RDIB | MDWD |
|---|---|---|
| Price | $11.95 | $17.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | 24.7K | ★ 97.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.97 |
| Revenue Next Year | $13.42 | $23.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.81 | $14.14 |
| 52 Week High | $17.40 | $22.51 |
| Indicator | RDIB | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 50.54 | 43.41 |
| Support Level | $9.23 | $16.97 |
| Resistance Level | $12.83 | $17.91 |
| Average True Range (ATR) | 1.69 | 0.70 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 34.09 | 8.38 |
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.